Peptide and peptide-based inhibitors of SARS-CoV-2 entry
Date
2020Author
Schütz, Desiree
Ruiz-Blanco, Yasser B.
Münch, Jan
Kirchhoff, Frank
Sanchez-Garcia, Elsa
Müller, Janis A.
Metadata
Show full item recordAbstract
To date, no effective vaccines or therapies are available against the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), the causative pandemic agent of coronavirus disease
2019 (COVID-19). Due to their safety, efficacy and specificity, peptide inhibitors hold great
promise for the treatment of newly emerging viral pathogens. Based on the known structures
of viral proteins and their cellular targets, antiviral peptides can be rationally designed and
optimized. The resulting peptides may be highly specific for their respective targets and
particular viral pathogens or exert broad antiviral activity. Here, we summarize the current
status of peptides inhibiting SARS-CoV-2 entry and outline the strategies used to design
peptides targeting the ACE2 receptor or the viral Spike protein and its activating proteases
furin, transmembrane serine protease 2 (TMPRSS2), or cathepsin L. In addition, we present
approaches used against related viruses such as SARS-CoV-1 that might be implemented for
inhibition of SARS-CoV-2 infection.
Palabras clave
Peptide drug; COVID-19; Coronavirus; Fusion; AntiviralLink to resource
https://doi.org/10.1016/j.addr.2020.11.007Collections
Estadísticas Google Analytics
Comments
Respuesta Comentario Repositorio Expeditio
Gracias por tomarse el tiempo para darnos su opinión.